Published in Drugs on August 01, 2000
Adverse reactions and drug-drug interactions in the management of women with postmenopausal osteoporosis. Calcif Tissue Int (2011) 1.50
The NSABP Study of Tamoxifen and Raloxifene (STAR) trial. Expert Rev Anticancer Ther (2009) 1.06
A rat model of epilepsy in women: a tool to study physiological interactions between endocrine systems and seizures. Endocrinology (2009) 0.84
High-dose diosgenin reduces bone loss in ovariectomized rats via attenuation of the RANKL/OPG ratio. Int J Mol Sci (2014) 0.84
Mechanism of raloxifene-induced upregulation of glutamate transporters in rat primary astrocytes. Glia (2014) 0.82
Safety profile of raloxifene as used in general practice in England: results of a prescription-event monitoring study. Osteoporos Int (2004) 0.82
CYP3A4-Mediated oxygenation versus dehydrogenation of raloxifene. Biochemistry (2010) 0.82
Effect of testosterone, raloxifene and estrogen replacement on the microstructure and biomechanics of metaphyseal osteoporotic bones in orchiectomized male rats. World J Urol (2009) 0.82
Treatment with Rhizoma Dioscoreae extract has protective effect on osteopenia in ovariectomized rats. ScientificWorldJournal (2014) 0.81
Raloxifene Administration in Women Treated with Long Term Gonadotropin-releasing Hormone Agonist for Severe Endometriosis: Effects on Bone Mineral Density. J Menopausal Med (2016) 0.80
Single and multiple ascending dose studies of a novel tissue-selective oestrogen receptor modulator, CHF 4227, in healthy postmenopausal women. Br J Clin Pharmacol (2007) 0.79
Managing the risk of invasive breast cancer in women at risk for breast cancer and osteoporosis: the role of raloxifene. Clin Interv Aging (2008) 0.76
The protective effect of Rhizoma Dioscoreae extract against alveolar bone loss in ovariectomized rats via regulating Wnt and p38 MAPK signaling. Nutrients (2014) 0.76
Comparative evaluation of raloxifene versus estrogen: Progestin on symptomatology, endometrium, and lipid profile in postmenopausal women. J Midlife Health (2010) 0.75
Extraintestinal Complications of Inflammatory Bowel Disease. Curr Treat Options Gastroenterol (2001) 0.75
Fragile X mental retardation protein is translated near synapses in response to neurotransmitter activation. Proc Natl Acad Sci U S A (1997) 4.03
Quinupristin-dalfopristin. Drugs (1996) 1.61
Bupropion: a review of its use in the management of smoking cessation. Drugs (2000) 1.32
Post-ECT cognitive defect and elevation of blood pressure. Br J Psychiatry (1979) 1.17
Alendronate: an update of its use in osteoporosis. Drugs (2001) 1.15
Miglitol: a review of its therapeutic potential in type 2 diabetes mellitus. Drugs (2000) 1.14
Tropisetron: an update of its use in the prevention of chemotherapy-induced nausea and vomiting. Drugs (2000) 1.10
Risperidone: a review of its use in the management of the behavioural and psychological symptoms of dementia. Drugs Aging (2000) 1.05
Aceclofenac: a reappraisal of its use in the management of pain and rheumatic disease. Drugs (2001) 1.04
Sevoflurane in paediatric anaesthesia: a review. Paediatr Drugs (2000) 1.02
Tianeptine: a review of its use in depressive disorders. CNS Drugs (2001) 1.02
Ebastine: an update of its use in allergic disorders. Drugs (2000) 0.98
Docetaxel. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in the management of metastatic breast cancer. Drugs (1996) 0.97
Paclitaxel. An update of its use in the treatment of metastatic breast cancer and ovarian and other gynaecological cancers. Drugs Aging (1998) 0.94
Dexrazoxane. A review of its use as a cardioprotective agent in patients receiving anthracycline-based chemotherapy. Drugs (1998) 0.91
Remifentanil. Drugs (1996) 0.90
Tolterodine: a review of its use in the treatment of overactive bladder. Drugs Aging (2001) 0.88
Levobupivacaine. Drugs (1998) 0.88
Butenafine. Drugs (1998) 0.87
Ropinirole: a review of its use in the management of Parkinson's disease. Drugs (2000) 0.87
The organic cofactor in plasma amine oxidase: evidence for pyrroloquinoline quinone and against pyridoxal phosphate. Biochem J (1987) 0.85
Unoprostone (isopropyl unoprostone) Drugs Aging (1996) 0.84
Balsalazide. Drugs (1998) 0.83
Insulin aspart. Drugs (1999) 0.81
Latanoprost. A review of its pharmacological properties, clinical efficacy and tolerability in the management of primary open-angle glaucoma and ocular hypertension. Drugs Aging (1996) 0.81
Edrecolomab (monoclonal antibody 17-1A). Drugs (1998) 0.80
Nisoldipine coat-core. A review of its pharmacodynamic and pharmacokinetic properties and clinical efficacy in the management of ischaemic heart disease. Drugs (1997) 0.79
Sdz asm 981. BioDrugs (2000) 0.79
Enoxacin: a reappraisal of its clinical efficacy in the treatment of genitourinary tract infections. Drugs (1996) 0.79
Celiprolol. An evaluation of its pharmacological properties and clinical efficacy in the management of hypertension and angina pectoris. Drugs Aging (1995) 0.78
Entacapone. A review of its use in Parkinson's disease. Drugs (1999) 0.78
Mitoxantrone. A review of its pharmacology and clinical efficacy in the management of hormone-resistant advanced prostate cancer. Drugs Aging (1997) 0.78
Topotecan: a review of its efficacy in small cell lung cancer. Drugs (1999) 0.78
Bicalutamide in advanced prostate cancer. A review. Drugs Aging (1998) 0.76
Irbesartan: an updated review of its use in cardiovascular disorders. Drugs (2000) 0.76
Lanoteplase. BioDrugs (2000) 0.76
Vorozole. Drugs Aging (1997) 0.75
Recombinant Factor VIIa. BioDrugs (1999) 0.75
Enoxaparin. A review of its clinical potential in the management of coronary artery disease. Drugs (1998) 0.75
Clobetasol propionate foam, 0.05%. Am J Clin Dermatol (2001) 0.75
The Yin and Yang of inflammation. Curr Mol Med (2014) 0.75
Gemtuzumab ozogamicin. Drugs (2001) 0.75
Morphological detection of plasma membrane changes during apoptosis using enhanced green fluorescent protein. Biotechniques (1999) 0.75
Levosalbutamol. BioDrugs (1999) 0.75
Estradiol-intranasal: a review of its use in the management of menopause. Drugs (2001) 0.75